IRVING, Texas and MONROVIA, Calif. , Jan. 5, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor , Inc. (NASDAQ: XNCR), a clinical-stage
MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 4, 2023-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief executive
MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 12, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 10, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 10, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the
-- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study -- -- Management to host conference call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 7, 2022-- Xencor, Inc.
-- Durable, dose-dependent and selective expansion of CD25 bright Tregs, reaching a 117-fold increase over baseline at the highest dose -- -- Single dose of XmAb564 well-tolerated with no reported serious adverse events -- -- First patient dosed in Phase 1b, multiple-ascending dose study in
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that clinical data from expansion cohorts in its Phase 1
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 31, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the
